These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 30269275)
41. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects. Lee HA; Kim S; Seo H; Kim S Expert Opin Investig Drugs; 2023; 32(10):959-966. PubMed ID: 37870163 [TBL] [Abstract][Full Text] [Related]
42. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S Expert Opin Biol Ther; 2024 Jul; 24(7):655-663. PubMed ID: 38349618 [TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants. Boyce M; Wilkes D; Kaito H; Takanuma M; Arai Y Int J Clin Pharmacol Ther; 2022 Jun; 60(6):280-290. PubMed ID: 35361328 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects. Yu KS; Jang IJ; Lim HS; Hong JH; Kim MG; Park MK; Cho DY; Park MS; Chung JY; Ghim JL; Lee S; Yoon SK; Kwon IS; Lee SJ; Kim SH; Bae YJ; Cha JB; Furst DE; Keystone E; Kay J Clin Transl Sci; 2021 Jul; 14(4):1280-1291. PubMed ID: 33503313 [TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial. Dong W; Chen M; Niu S; Wang B; Xia L; Wang J; Shen T; Wang Q; Lv J; Liu G; Fan H; Xie Z; Xie F; An Y; Zheng Q; Rao H; Song H; Fang Y Expert Opin Biol Ther; 2022 Feb; 22(2):253-262. PubMed ID: 34236011 [TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males. Vogg B; Poetzl J; El Galta R; Fuhr R; Schwebig A; Sekhar S Expert Opin Biol Ther; 2024; 24(1-2):91-100. PubMed ID: 38269652 [TBL] [Abstract][Full Text] [Related]
48. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects. Shin D; Kim Y; Kim YS; Körnicke T; Fuhr R BioDrugs; 2015 Dec; 29(6):381-8. PubMed ID: 26577771 [TBL] [Abstract][Full Text] [Related]
49. Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study. Jeong H; Kang T; Lee J; Im S Int J Clin Pharmacol Ther; 2024 May; 62(5):231-240. PubMed ID: 38174886 [TBL] [Abstract][Full Text] [Related]
50. A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects . Zhang H; Zhu X; Wei H; Li C; Chen H; Li X; Wu M; Liu J; Chen G; Zhou H; Zheng S; Ding Y Int J Clin Pharmacol Ther; 2019 Mar; 57(3):167-174. PubMed ID: 30663977 [TBL] [Abstract][Full Text] [Related]
51. Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants. Yonemura T; Yazawa R; Haranaka M; Kawakami K; Takanuma M; Kanzo T; Stefanidis D; Arai Y BMC Pharmacol Toxicol; 2022 Jan; 23(1):6. PubMed ID: 34998419 [TBL] [Abstract][Full Text] [Related]
52. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects. Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017 [TBL] [Abstract][Full Text] [Related]
53. A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects. Farmahini Farahani M; Maghzi P; Jafari Aryan N; Payandemehr B; Soni M; Azhdarzadeh M Expert Opin Investig Drugs; 2020 Dec; 29(12):1443-1450. PubMed ID: 33016783 [TBL] [Abstract][Full Text] [Related]
54. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects. Singh I; Attrey A; Garg A; Patel R; Jose V Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287 [TBL] [Abstract][Full Text] [Related]
55. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects. Bush J; Kawakami K; Muniz R BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742 [TBL] [Abstract][Full Text] [Related]
56. A randomized, double-blind, single-dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab. Schwabe C; Cole A; Espigares-Correa A; Beydon ME; Florez-Igual A; Queiruga-Parada J Pharmacol Res Perspect; 2023 Apr; 11(2):e01070. PubMed ID: 36914963 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects. Zhang Q; Sun C; Wu J; Wu J; Zhang X; Liu Y; Dou C; Qin H; Zhang Q; Zhou R; Hu W Expert Opin Biol Ther; 2023; 23(8):727-735. PubMed ID: 36880118 [TBL] [Abstract][Full Text] [Related]
58. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx Yao F; Wang C; Ding J; Zhang Q; Zheng L; Zhang Q; Yang T; Zhang X; Shan Y; Hou S; Wang H; Zhou R; Hu W Drug Des Devel Ther; 2024; 18():3891-3901. PubMed ID: 39224901 [TBL] [Abstract][Full Text] [Related]
59. A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects. Hanes V; Chow V; Stewart T; Puri A Cancer Chemother Pharmacol; 2021 Nov; 88(5):879-886. PubMed ID: 34355250 [TBL] [Abstract][Full Text] [Related]
60. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Knight B; Rassam D; Liao S; Ewesuedo R Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]